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PMP–diketopiperazine adducts form at the active
site of a PLP dependent enzyme involved in
formycin biosynthesis†
Sisi Gao, ab Huanting Liu, b Vale´rie de Cre´cy-Lagard, c Wen Zhu, d
Nigel G. J. Richards ef and James H. Naismith *ghi
ForI is a PLP-dependent enzyme from the biosynthetic pathway of
the C-nucleoside antibiotic formycin. Cycloserine is thought to
inhibit PLP-dependent enzymes by irreversibly forming a PMP–
isoxazole. We now report that ForI forms novel PMP–diketopiperazine
derivatives following incubation with both D and L cycloserine. This
unexpected result suggests chemical diversity in the chemistry of
cycloserine inhibition.
As part of investigations into the C-nucleoside formycin A (8-aza-
9-deazaadenosine, Fig. 1) biosynthetic gene cluster from Streptomyces
kaniharaensis,1 we have characterised a pyridoxal 50-phosphate (PLP)
dependent aminotransferase (ForI) that aminates a pathway
intermediate. C-Nucleosides are very interesting potential med-
icinal compounds that in addition to formycin A2–4 include
showdomycin,5 minimycin6 and pyrazomycin.7 Schramm and
colleagues, inspired by C-nucleosides, devised immunocillins8
which have considerable promise in treating a variety of serious
diseases.8–10 C-Nucleosides are stable to acid and phosphorolysis by
purine nucleoside phosphorylase,11 and thus may retain the utility
of N-nucleosides known to have importantmedicinal activities while
having improved pharmacokinetic properties.12–14
Given that the heterocyclic substrate of ForI remains uncon-
firmed and not available, we probed the behaviour of ForI
with D- and L-cycloserine, which are well known inhibitors of
PLP-dependent enzymes, including transaminases,15 racemases16
and decarboxylases.17 D-Cycloserine is a natural product used as a
broad spectrum antibiotic,18 whose primary target is the bacterial
PLP-dependent alanine racemase.19,20 Both enantiomers of cyclo-
serine are known to form external aldimine pyridoxamine
50-phosphate (PMP) adducts, which convert irreversibly to stable
PMP–isoxazoles. We now report that cycloserine forms an adduct
with ForI but unexpectedly it is a novel PMP–diketopiperazine
adduct.
Recombinant ForI was overexpressed in Escherichia coli and
purified by metal aﬃnity and gel filtration chromatography.22
The enzyme purifies with bound PLP and exists as a dimer (Fig. S1
and Table S1, ESI†). Crystals were obtained in the presence of PLP
and the structure solved to 1.18 Å resolution (Fig. 2a) by molecular
replacement using the thermostable omega-transaminase from
Sphaerobacter thermophilus (PDB: 5D95) as amodel (Table S2, ESI†).
Residues 3 to 417 were located experimentally (Fig. 2a); the
missing nine residues we assume to be conformationally flexible.
ForI belongs to the aspartate aminotransferase (A-AT) superfamily
with 50% sequence similarity to PLP-dependent glutamate-1-
semialdehyde aminotransferase (PDB: 3K28) from Bacillus
anthracis (Fig. S2, ESI†).23 Structurally24,25 ForI most closely
resembles glutamate-1-semialdehyde aminomutase (GSAAT)
(PDB: 2GSA).26 ForI possesses the mixed b-sheet and three-
stranded antiparallel b-sheet insertion characteristic of the PLP
dependent aspartic aminotransferase family (Fig. 2a).27 GSAAT and
ForI share 30% sequence identity, and pairwise superposition
Fig. 1 Proposed reaction catalysed by ForI. R = CH2COO
 for L-Asp or
(CH2)2COO
 for L-Glu.21 L-Cycloserine is shown.
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gives an r.m.s.d. of 1.3 Å over 422 Ca atoms (Fig. 2b). Electron
density shows that PLP forms a Schiﬀ base (internal aldimine)
with the active site Lys 262, (Fig. 3a).28 The dimer (Fig. 2c) arises
from crystal symmetry.29,30 The predicted active site of ForI
comprises residues from two monomers (Fig. 3b), indicating the
dimer to be the functional unit. The resolution of the structure
allows for visualisation of extensive hydration at the active site and
water–PLP hydrogen bonds. PLP makes multiple contacts with the
protein, broadly similar to those described for the GSAAT
structure.31 In GSAAT residues Ala 161 to Ser 173 form an a-helix
whose N-terminus that partly form the active site. The equivalent
residues in ForI adopt a different arrangement creating a cavity
(pocket) adjacent to PLP. The substitution of Met 248 in GSAAT by
Gly 238 in ForI also leads to a more open active site (Fig. S3, ESI†).
The catalytically important Glu 406 in GSAAT26 has no functional
equivalent in ForI. The equivalent region, centred on Ser 389 in ForI,
adopts a different conformation. In ForI, Trp 206 and Arg 207 which
are not present in GSAAT, only partially fill the pocket. The
consequence of these changes is that the pocket adjacent to the
co-factor is larger in ForI (Fig. 3c).
Incubating ForI with L-Glu shows a rapid change in the
UV-vis spectrum (Fig. S4, ESI†). We incubated crystals of ForI
with L-Glu for 20 minutes and collected a 1.56 Å resolution data
set. The electron density clearly indicates that the pyridoxal
co-factor is unattached to the enzyme, suggesting it to be PMP
(Fig. 3d). Despite numerous attempts we have not observed
density for L-Glu or a-KG. PMP forms a 3.2 Å hydrogen bonding
interaction with e-N of Lys 262. The plane of the PMP molecule
has rotated by 221 relative to PLP (Fig. 3e). Residues Tyr 141 and
Trp 206 are slightly displaced, Arg 207 switches to an alternate
conformation (Fig. 3e). Accompanying these changes in protein
structure are shifts in water molecule locations. These structural
changes result in the pocket adjacent to the cofactor (bounded
by Ala 25, Thr 60, Tyr 141, Trp 206) enlarging further and
becoming more open to solvent.
Incubation of ForI with either D- or L-cycloserine immediately
shows changes in the UV-vis spectrum (Fig. 4a and b). Spectral
changes for the L-enantiomer appear to complete faster (o1 h)
than the D enantiomer (o30 h). After incubating the protein at
4 1C with either 10 mM D or L cycloserine overnight, the protein
was crystallised at pH 8 with 10 mM cycloserine, crystals were
harvested on day 3 and 1.5 Å diﬀraction data collected (Table S2,
ESI†). Mass spectrometry (Fig. S8, ESI†) and unbiased electron
density (Fig. 4c and d) identified the formation of external aldimine
PLP–diketopiperazine adducts, that have retained the stereo-
chemistry of the cycloserine enantiomer used in soaking.
In each external aldimine complex, the atoms of the diketo-
piperazine adduct originating from PLP adopt the same positions
as observed for the PMP structure. Tyr 141 adopts the same
conformer seen in the PMP structure. In both structures the
Fig. 2 Structure of ForI. (a) Cartoon representation monomer of ForI, the
conserved insertions characteristic of aspartate aminotransferases are
highlighted in green. PLP is shown in spheres, carbon yellow, nitrogen
blue and oxygen red. (b) ForI colored as (a), superimposed on glutamate-1-
semialdehyde aminomutase in orange. (c) ForI is a dimer, the other
monomer is colored salmon, PLP is colored as (a).
Fig. 3 ForI active site (a) unbiased Fo–Fc map contoured at 3s for the
internal aldimine. (b) Hydrogen bonding interaction of PLP with surrounding
water molecules and other residues. Residues from monomer A have
carbons in yellow; monomer B salmon. (c) The ForI cavity is shown in red.
(d) Unbiased Fo–Fc map contoured at 3s for PMP. (e) PMP is rotated relative
to PLP form resulting in conformational changes in active site residues.
ForI–PLP carbons in yellow; ForI–PMP grey.
Fig. 4 ForI and cycloserine. (a) UV-vis spectrum with L-cycloserine
(b) UV-vis spectrum with D-cycloserine (c) unbiased Fo–Fc map contoured
at 3s PMP–diketopiperazine from L-cycloserine. (d) Unbiased Fo–Fc map
contoured at 3s for PMP–diketopiperazine from D-cycloserine. (e) Chemical
structure of PMP–diketopiperazine adduct. (f) Active site amino residues
exhibit different configuration for L-configured (yellow carbons) and
D-configured (grey carbons) diketopiperazine rings. (g) L-Configured diketo-
piperazine adduct hydrogen bonds with water molecules as red spheres.
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diketopiperazine ring occupies the pocket adjacent to the cofactor
(Fig. 4f and g). However, the orientation and thus the details of the
interactions with the protein of the diketopiperazine rings in this
pocket are diﬀerent (Fig. 4g).
In the L-cycloserine derived complex Trp 206 has adjusted its
conformation in order to make p-stacking interactions with
the diketopiperazine ring (Fig. 4f). Arg 207 adopts a diﬀerent
conformation than seen in either PLP or PMP structures, in this
conformation it makes only a few van der Waals contacts with
the adduct. The polar atoms in diketopiperazine ring make a
series of hydrogen bonds to water molecules which bridge to
the protein (Fig. 4g). The diketopiperazine ring arising from
D-cycloserine does not p-stack with Trp 206 which is found in
the same conformation seen in the PMP complex. The residue
does make van der Waals interactions with the diketopiperazine
but many fewer than seen in the L-configured adduct. Arg 207
adopts the conformer seen in the PMP structure and has no
contact with the adduct (Fig. 4f). Tyr 141 makes more inter-
actions with the D-configured diketopiperazine ring than were
seen for Try 141 with the diketopiperazine ring that arose from
L-cycloserine. The polar atoms of this adduct also make hydro-
gen bonds to water molecules (Fig. S5, ESI†). The diketopiper-
azine molecule may thus partly mimic the external aldimine of
the aromatic planar heterocyclic ForI substrate (Fig. 1) and the
possibility of p-stack with Trp 206 is especially suggestive.32 We note
that the diketopiperazine binding pocket does not exist in GSAAT
where Ser 163, Asn 217 and Glu 406 would clash with the molecule
(Fig. S5, ESI†) and may reflect the diﬀerence in substrate.
The structure of GSAAT with PMP and gabaculine (PDB:
3GSB) has been reported.26 Gabaculine is located in a pocket
adjacent to PLP but this location in ForI is blocked by Arg 23
(Fig. S5, ESI†). The more distantly related Streptomyces fradiae
enzyme NeoB (PDB: 6CBL) (24% sequence identity, 1.94 Å
r.m.s.d. 337 Ca’s) (Fig. S2, ESI†), catalyses the amination of
aminoglycoside antibiotics and the external aldimine with the
D-neosamine has been reported.33 The sugar ring attached to
the cofactor sits in the same pocket as the diketopiperazine but
makes diﬀerent interactions. The other sugar would clash with
the main chain at Asn 152 in ForI (Fig. S6, ESI†) and both
diketopiperazines would clash with Tyr 341 of NeoB.
The observation of PMP–diketopiperazine rather than
PMP–isoxazole adduct was unexpected. The formation of the
PMP–isoxazole proceeds via an external aldimine followed by
tautomerisation which is catalysed by the key lysine (Scheme 1).34
Two related questions thus arise; why has a diketopiperazine not
been observed before and why do we observe the PMP–diketopi-
perazine adduct?
The structure of the PMP–isoxazole adduct has most recently
been reported for the PLP-dependent MtIlvE enzyme (PDB:
5U3F) from Mycobacterium tuberculosis which catalyses the
L-glutamate-dependent transamination of a-ketoisocaproate,
a-keto-methyloxopentanoic acid and a-ketoisovalerate.34 MtIlvE
has a very different structure to ForI (10% sequence identity,
4.8 Å r.m.s.d. 71 Ca’s) (Fig. S2, ESI†). Using only the atoms in
the pyridoxal rings to superimpose the structures shows that
the PLP environment is very different in the two enzymes and a
diketopiperazine adduct would clash with residues in MtIlvE.
Other PLP D-cycloserine adduct complexes (2RJH, 1I2L, 1D7S,
5FAJ, 4IUT, 3TCM, 4D9F) have been reported with the non-
aromatic D-configured external aldimine whilst others (3E6E,
1VFS, 1EPV, 2DAA) contain what appears, in the light of MtIlvE
study34 to be the PMP–isoxazole. Complexes following L-cyclo-
serine incubation (4OMA, 1D7U, 1VFT 1NIU, 1MDZ) show the
PMP–isoxazole although one (4D9E) includes a non-aromatic,
L-ketamine. Desulfhydrase racemase, lyase, and alanine amino-
transferase enzymes (4D9E, 4D9F, 1VFT, 1VFS, 3E6E, 2RJH,
1EPV, 1I2L, 2DAA, 5FAJ, 4LUT, 3TCM) have very different
proteins structures, thus as with MtIlvE the atoms of pyridoxal
rings rather than those in protein were used to superimpose the
structures. Of these structures, only the active sites of 4D9E,
4D9F, 2RJH, 1VFS, 1VFT, 1I2L, 2DAA and 4LUT seem large
enough (or sufficiently exposed to solvent) to accommodate a
diketopiperazine adduct but would require some structural
adjustments of side chains. Where the fold is sufficiently con-
served to permit protein superposition (1D7S, 1D7U, 4OMA, 1NIU,
1MDZ), differences in the loops at the active site give rise to clashes
that would require large main chain movements to accommodate
a PMP–diketopiperazine. These structural difference may
explain why diketopiperazine adducts were not reported for
these enzymes.
Why is a PMP–diketopiperazine adduct seen in ForI? The
pH, times and concentrations of protein and cycloserine used in
our crystallisation and mass spectrometry experiments are com-
parable to other studies.34 Neither mass spectrometry nor NMR
analysis of fresh L-cycloserine solution shows diketopiperazine;
the supplier reports less than 1% impurity. Diketopiperazine
forms spontaneously in cycloserine solutions; at 25 1C, pH 6
and 10 mM concentration the half-life of cycloserine is 10 h.35
The estimated half-life of cycloserine under crystallisation con-
ditions (pH 8 and 4 1C) and mass spectrometry conditions (pH 8
and 4 1C) is 41000 h.35 The crystallisation experiment used
10 mM cycloserine with 1 mM protein for 84 h and mass
spectrometry 2 mM cycloserine in solution with 0.1 mM protein
for 14 h. The oxime of diketopiperazine is expected to be more
reactive than the amine of cycloserine towards PLP. It is
plausible that the diketopiperazine adducts arise from diketo-
piperazine present in solution that preferentially react with PLP.
The alternative explanation is that conversion of cycloserine
to diketopiperazine is catalysed by ForI. PLP has been reported
to catalyse diketopiperazine formation.36 A plausible chemical
mechanism is proposed in Scheme 2. The initial step is formation
Scheme 1 The formation of the PMP–isoxazole from D-cycloserine
(adopted from ref. 34).
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of the external aldimine with cycloserine, common to all PLP
enzymes. In ForI, we suggest this aldimine is stable enough and
the active site large enough for a second molecule to enter the
active site and ring open the cycloserine external aldimine
(Scheme 2) before the irreversible PMP–isoxazole forms. We
note that the positively charged Lys 262 is positioned such that
it could stabilise the negatively charged tetrahedral intermedi-
ate that ring opening steps create (Scheme 2) and thus catalyse
this reaction. The ring opened aldimine would then undergo a
series of re-arrangements facilitated by proton shuttling and
charge stabilisation. The large number of water molecules and
hydrophilic residues at the active site, would be expected to
assist this process. The difference in the rates of formation of the
adducts, we suggest would arise from the favourable p-stacking
interaction with Trp 206 seen only for L-configured diketopi-
perazine. Irrespective whether diketopiperazine is formed in
solution or catalyzed by ForI, we conclude it is the enzyme’s
large polar cavity that favors formation the PMP–diketopiper-
azine adduct.
The covalent inhibition of PLP enzymes by cycloserine is at
the heart of an antimicrobial agent. Prevailing wisdom is that
this inhibition results from formation of a PMP–isoxazole
adduct. A study of the SPT family of PLP enzymes proposed
the SPT enzyme catalysed ring opening of the external cyclo-
serine aldimine by water.37 Interestingly, diketopiperazine has
been reported to inhibit PLP dependent aspartate–glutamate
transaminase38 and to be active against M. tuberculosis.39 We
suggest that PLP/cycloserine chemistry remains far from a fully
understood process and it is likely there will be more surprises.
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scholar at Sichuan University.
Conflicts of interest
There are no conflicts to declare.
Notes and references
1 Y. Ko, S.-A. Wang, Y. Ogasawara, M. W. Ruszczycky and H. Liu, Org.
Lett., 2017, 19, 1426–1429.
2 D. C. Ward, W. Fuller and E. Reich, Proc. Natl. Acad. Sci. U. S. A.,
1969, 62, 581–588.
3 M. C. Long and W. B. Parker, Biochem. Pharmacol., 2006, 71, 1671–1682.
4 K. A. Cornell, W. E. Swarts, R. D. Barry and M. K. Riscoe, Biochem.
Biophys. Res. Commun., 1996, 228, 724–732.
5 M. Ohno, Y. Ito, M. Arita, T. Shibata, K. Adachi and H. Sawai,
Tetrahedron, 1984, 40, 145–152.
6 Kiyoshi Isono and R. J. Suhadolnik, J. Antibiot., 1977, 30, 272–273.
7 P. G. Canonico, P. B. Jahrling and W. L. Pannier, Antiviral Res., 1982,
2, 331–337.
8 G. A. Kicska, L. Long, H. Horig, C. Fairchild, P. C. Tyler, R. H.
Furneaux, V. L. Schramm and H. L. Kaufman, Proc. Natl. Acad. Sci.
U. S. A., 2001, 98, 4593–4598.
9 G. B. Evans, P. C. Tyler and V. L. Schramm, ACS Infect Dis., 2018, 4, 107–117.
10 E. O. Freitas, D. Nico, M. V. Alves-Silva, A. Morrot, K. Clinch,
G. B. Evans, P. C. Tyler, V. L. Schramm and C. B. Palatnik-de-
Sousa, PLoS Neglected Trop. Dis., 2015, 9, e0004297.
11 A. Bzowska, Modified Nucleosides: in Biochemistry, Biotechnology and
Medicine, 2018, pp. 473–510.
12 E. De Clercq, Med. Res. Rev., 2012, 33, 1215–1248.
13 M. Privatdegarilhe and J. De Rudder, C. R. Hebd. Seances Acad. Sci.,
1964, 259, 2725.
14 V. Heinemann, L. W. Hertel, G. B. Grindey and W. Plunkett, Cancer
Res., 1988, 48, 4024–4031.
15 T. S. Soper and J. M. Manning, J. Biol. Chem., 1981, 256, 4263–4268.
16 T. D. Fenn, G. F. Stamper, A. Anthony, A. Morollo and D. Ringe,
Biochemistry, 2003, 42, 5775–5783.
17 V. N. Malashkevich, P. Strop, J. W. Keller, J. Jansonius and
M. D. Toney, J. Mol. Biol., 1999, 294, 193–200.
18 M.-L. Svensson and S. Gatenbeck, Arch. Microbiol., 1982, 131, 129–131.
19 J. Strominger, E. Ito and R. H. Threnn, J. Am. Chem. Soc., 1960, 82, 998–999.
20 F. C. Neuhaus and J. L. Lynch, Biochemistry, 1964, 3, 471–480.
21 M. Zhang, P. Zhang, G. Xu, W. Zhou, Y. Gao, R. Gong, Y.-S. Cai, H. Cong,
Z. Deng, N. P. J. Price, X. Mao and W. Chen, bioRxiv, 2019, 728154.
22 H. Liu and J. H. Naismith, Protein Expression Purif., 2009, 63, 102–111.
23 H. Ge, X. Lv, J. Fan, Y. Gao, M. Teng and L. Niu, Biochem. Biophys.
Res. Commun., 2010, 402, 356–360.
24 C.-H. Tung, J.-W. Huang and J.-M. Yang, Genome Biol., 2007, 8, R31.
25 J.-M. Yang and C.-H. Tung, Nucleic Acids Res., 2006, 34, 3646–3659.
26 M. Hennig, B. Grimm, R. Contestabile, R. A. John and
J. N. Jansonius, Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 4866–4871.
27 M. D. Toney, Arch. Biochem. Biophys., 2014, 544, 119–127.
28 J. N. Jansonius, Curr. Opin. Struct. Biol., 1998, 8, 759–769.
29 D. Schneidman-Duhovny, Y. Inbar, R. Nussinov and H. J. Wolfson,
Nucleic Acids Res., 2005, 33, W363–W367.
30 D. Schneidman-Duhovny, Y. Inbar, R. Nussinov and H. J. Wolfson,
Proteins: Struct., Funct., Bioinf., 2005, 60, 224–231.
31 S. F. Altschul, J. C. Wootton, E. M. Gertz, R. Agarwala, A. Morgulis,
A. A. Schaﬀer and Y.-K. Yu, FEBS J., 2005, 272, 5101–5109.
32 S.-A. Wang, Y. Ko, J. Zeng, Y. Geng, D. Ren, Y. Ogasawara, S. Irani,
Y. Zhang and H. Liu, J. Am. Chem. Soc., 2019, 141, 6127–6131.
33 G. T. Dow, J. B. Thoden and H. M. Holden, Protein Sci., 2018, 27,
945–956.
34 T. M. Amorim Franco, L. Favrot, O. Vergnolle and J. S. Blanchard,
ACS Chem. Biol., 2017, 12, 1235–1244.
35 A. P. Kondrat’eva, B. P. Bruns and G. S. Libinson, Pharm. Chem. J.,
1971, 5, 356–360.
36 R. Khomutov, M. Karpeisky and E. Severin, Chemical and Biological
Aspects of Pyridoxal Catalysis, 1963, pp. 313–321.
37 J. Lowther, B. A. Yard, K. A. Johnson, L. G. Carter, V. T. Bhat, M. C. C.
Raman, D. J. Clarke, B. Ramakers, S. A. McMahon, J. H. Naismith and
D. J. Campopiano, Mol. BioSyst., 2010, 6, 1682–1693.
38 M. Karpeisky, R. Khomutov, E. Severin and Y. Breusov, Chemical and
Biological Aspects of Pyridoxal Catalysis, 1963, pp. 323–331.
39 J. Michalsky, J. Ctvrtnik, Z. Horakova and V. Bydzovsky, Exierientia,
1962, 18, 217–218.
Scheme 2 A hypothetical chemical mechanism for ForI-catalysed for-
mation of the PMP–diketopiperazine adduct from L-cycloserine.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
no
ve
m
be
r 2
01
9.
 D
ow
nl
oa
de
d 
on
 0
3.
01
.2
02
0 
14
:1
6:
49
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
